The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MGTX | +51.37% | -33.21% | -7.75% | -41% |
| S&P | +18.37% | +110.18% | +16.02% | +147% |
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company was founded on March 20, 2015 and is headquartered in New York, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.69M | 1208.9% |
| Gross Profit | -$2.18M | 26.0% |
| Gross Margin | -58.93% | 983.6% |
| Market Cap | $523.98M | 93.5% |
| Market Cap / Employee | $1.38M | 0.0% |
| Employees | 381 | -10.4% |
| Net Income | -$38.80M | 20.2% |
| EBITDA | -$41.60M | 2.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $32.17M | -67.8% |
| Accounts Receivable | $2.32M | 42.4% |
| Inventory | 0.3 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $77.82M | -6.6% |
| Short Term Debt | $2.65M | -37.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -67.69% | -35.4% |
| Return On Invested Capital | -52.23% | -14.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$45.18M | -117.4% |
| Operating Free Cash Flow | -$43.95M | -125.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.37 | 4.94 | 7.84 | 15.64 | 603.52% |
| Price to Sales | 21.45 | 14.35 | 15.53 | 13.86 | -58.47% |
| Price to Tangible Book Value | 3.41 | 4.99 | 7.93 | 16.02 | 614.21% |
| Enterprise Value to EBITDA | -7.14 | -16.14 | -14.29 | -13.79 | 127.62% |
| Return on Equity | -94.0% | -143.5% | -216.1% | -379.5% | 314.74% |
| Total Debt | $86.74M | $84.80M | $80.88M | $80.47M | -8.10% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
